MENNICKENT, S.; MIRANDA, A.; GÓMEZ, C.; VEGA, M.; RÍOS, G.; DE DIEGO, M.; AVELLO, M.; SCHULZ, B.
Journal of Planar Chromatography 28 (2015) 251-255.
DOI: 10.1556/1006.2015.28.3.10
Abstract
Alzheimer’s dementia (AD) is the most common type of de- mentia in clinical and autopsy surveys. AD is a neurodegenerative disorder that is estimated to affect 15 million people around the world. By 2050, the number of patients with AD could be as high as 25 million. The current prevalence of AD in the U.S. is estimated at 4.5 million, a number expected to rise threefold over the next 50 years as the population ages. Alzheimer’s disease is the seventh leading cause of all deaths in the United States and the fth leading cause of death among Americans older than 65 years.
Significant cost implications related to Alzheimer’s disease and other dementias include an estimated 148 billion dollars annually. The public health impact of Alzheimer’s disease is very important, including incidence and prevalence, mortality, life- time risks, direct and indirect costs, and impact on family caregivers. Therefore, although there is no cure for patients with this disorder today, treatments approved by the US Food and Drug Administration (FDA), including the use of acetylcholinesterase inhibitors and an N-methyl-D-aspartate (NMDA) receptor antagonists are very useful to improve some symptoms, as aggressive behavior and spacetime knowledge.